HOSPITAL UNIVERSITARIO RUBER
Departamento
Pontifícia Universidade Católica do Rio Grande do Sul
Porto Alegre, BrasilPublicaciones en colaboración con investigadores/as de Pontifícia Universidade Católica do Rio Grande do Sul (6)
2022
-
GLORIA: phase III, open-label study of adagloxad simolenin/OBI-821 in patients with high-risk triple-negative breast cancer
Future Oncology, Vol. 18, Núm. 34, pp. 3801-3813
-
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
New England Journal of Medicine, Vol. 387, Núm. 3, pp. 217-226
2020
-
Enhancing global access to cancer medicines
CA Cancer Journal for Clinicians, Vol. 70, Núm. 2, pp. 105-124
-
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
The Lancet, Vol. 396, Núm. 10265, pp. 1817-1828
2017
-
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy
Breast Cancer Research, Vol. 19, Núm. 1
-
Research needs in breast cancer
Annals of Oncology, Vol. 28, Núm. 2, pp. 208-217